Corporate News

09 May 2017

amp biosimilars AG (Biosilu Healthcare AG) extraordinary general meeting

Frankfurt am Main, May 9, 2017 – amp biosimilars AG (ISIN: DE000A0SMU87, WKN A0SMU8), listed on Munich Stock Exchange’s Open Market, held its extraordinary general meeting on May 8, in Berlin with 72.43 percent of the share capital represented. All management proposals were accepted unanimously.

Read More
03 April 2017

amp biosimilars AG successfully completes cash capital increase

Frankfurt am Main, April 3, 2017 – amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has successfully completed its share capital increase resolved today, with approval of the supervisory board, from EUR 2,050,000.00 to EUR 2,075,000.00 by issuing 75,000 new no-par value bearer shares against cash contribution partially utilizing the existing authorized capital and excluding the shareholders’ subscription rights.

Read More
30 March 2017

amp biosimilars AG adjusts company’s business model

Frankfurt am Main, March 30, 2017 – the management of amp biosimilars AG, Frankfurt am Main, (ISIN DE000A0SMU87, WKN A0SMU8) has adjusted the company‘s business model.

Read More
14 March 2017

amp biosimilars AG: Dr Stefan Elßer appointed to the Supervisory Board

On March 14, 2017, Dr Stefan Elßer has appointed by the court of Frankfurt am Main to the Supervisory Board of amp biosimilars AG. Dr Elßer replaces Dr Thomas Zimmer whose term of office ended by the end of the annual general meeting 2016.

Read More
14 September 2016

Umbau des Managements

amp biosimilars AG schließt den planmäßigen Umbau des Managements ab.

Öffnen Sie die PDF-Datei hier.

Read More
01 September 2016

Ordentliche Hauptversammlung der amp biosimilars AG

Alle Beschlussvorschläge der Gesellschaft wurden einstimmig angenommen
 

Öffnen Sie die PDF-Datei hier.

Read More
22 July 2016

Jahresabschluss 2015

Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR.
 

Öffnen Sie die PDF-Datei hier.

Read More
18 July 2016

Änderungen im Vorstand

Veröffentlichung einer Insiderinformation gemäß Artikel 17 MAR.
 

Öffnen Sie die PDF-Datei hier.

Read More
28 June 2016

amp biosimilars announces Klaus K. Wilgenbus as new CEO

amp biosimilars AG (ISIN: DE000A0SMU87) today announced that Klaus K. Wilgenbus will lead the firm as the new CEO from July 1, 2016.

 

Click the link to download the pdf.

Read More